Fig. 8
From: Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy
In vivo antitumor study with CT26-bearing BALB/c mice. CT26 tumor-bearing mice were intraperitoneally injected with PBS, free PD-1 aptamer, PD1-polyA, free AS1411 aptamer, AS1411-polyT, or BiApt every 3d for a total of 4 injections (arrows). Tumor volume and body weight were recorded and shown (n = 8, mean + SEM). Star indicates statistically significant differences (p < 0.05), and “ns” indicates differences that are not statistically significant